JO
TXG icon

John Overdeck’s 10x Genomics TXG Stock Holding History

John Overdeck’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,500
Closed -$670K – 4310
2021
Q4 		$670K Buy
+4,500
New +$689K ﹤0.01% 2945

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's TXG Position: Q2 2026 in Review

John Overdeck reduced its 10x Genomics (TXG) stake by 65% in Q2 2026, selling an estimated $6.83M and leaving 141,776 shares worth $5.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

John Overdeck first reported a position in TXG in Q4 2020 and has held it in 20 quarters since. The position peaked at $18.9M in Q4 2024. 389 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • John Overdeck held 141,776 shares of 10x Genomics worth $5.44M as of Q2 2026.
  • John Overdeck sold 260,651 10x Genomics shares in Q2 2026, an estimated $6.83M.
  • 10x Genomics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2069 holding.
  • John Overdeck first reported a position in 10x Genomics in Q4 2020 and has held it in 20 quarters since.
  • John Overdeck's 10x Genomics position peaked at $18.9M in Q4 2024.
  • 389 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.